In this episode we visit the front lines of science. We’re all aware of the health care workers on the front lines of treatment, but what is it like to do research on the novel […]
Michael Heltzen is the CEO of Cardea Bio. He envisions a time when biology is part of the technology. What exactly does that mean? We currently use aspects of biology to observe or manipulate living […]
As we shelter in place in the midst of a pandemic, the world waits for science to rescue us with testing, treatments and/or a vaccine. But how do we get more people to connect with […]
Many business disasters are the result of bad decision making. But how do we learn to make better decisions, given all the effort that goes into planning, SWOT analyses and so on? Gleb Tsipusky has […]
Back in November, I spoke to?Mysty Rusk and Jason Scharf about the upcoming?(now complete) San Diego Angel Conference. In this episode, Peter Teriete describes his experience as a participant. His company,?TumorGen, enrolled in the conference […]
Infectious disease is getting a lot of attention right now because we are in the middle of the Corona Virus pandemic. In this episode (recorded back in January),? Dr. Molly Matty helps us explore how […]
Self doubt and the expectations of others can be a heavy load to carry. Debbie Chen, Founder and CEO of Hydrostasis, managed to relieve herself of those burdens and finally discover what success means to […]
How do you avoid the terrible stereotype of the poor scientific speaker? Scott Stiefvater calls himself the (anti) Presentation Coach. His approach is based on the fact that there are no neurons in the brain […]
Artificial intelligence is already making its way into healthcare and allowing for improvements patient care. The possibilities go way beyond what you may have imagined. In this episode, Dr Eric Topol, Executive Vice President at […]
Robin Toft is the Chairman and Founder of?The Toft Group, an executive search firm and author of the book: We Can: The Executive Woman’s Guide to Career Advancement. In this episode she shares three things […]
In this episode, we explore where funding typically comes from at different stages in the evolution of a biotech company, along with some relatively new sources of funding that you may not have been aware […]
This is an optional event before SDBN Speed Networking February 3rd, attend both and you’ll learn and connect even more. Do you work in the area of protein degradation, or are you interested in learning […]
Do you work in the area of protein degradation, or are you interested in learning more about it and connecting with others? If so, join us for a group discussion about the current progress and […]
Paul Mola is the Founder and CEO of Roswell Biotechnologies. They are working toward the goal of the $100 dollar genome via molecular electronics.? In a nutshell, they incorporate DNA polymerase into a circuit and […]
Sheila Gujrathi is the CEO of Gossamer Bio. She feels strongly about the importance of a thriving corporate culture to the success of an organization.In this interview, she explained to me the values that are […]
Paul Bromann is a Senior Manager of Scientific Affairs at Illumina. He also hosts the Illumina Genomics podcast. In this episode he explains why Illumina started a podcast and what the goals are. Because he […]
Do you work in the area of immuno-oncology? If so, join us for a group discussion about the current progress and challenges in the field, led by Eurofins Discovery lead scientists. Meet experts and local […]
Anne Marbarger is the Executive Director of Padres Pedal the Cause. She joined me to talk about this organization that has raised just over ten million dollars in the last six years to fund research […]
? The bacteria in your gut play a big role in your health. And maybe more than you imagined. So much so that Stephanie Culler wants you to send her your poop. She is the […]
Diverse teams have been shown to be more innovative. But diversity alone is not sufficient. Team members need to feel included in whatever task is at hand. Otherwise, employee engagement suffers. Denise Pirrotti Hummel is […]
Christina Waters is the CEO and president of RARE Science. The mission is?to identify more immediate therapeutic solutions for kids with rare diseases. There may be 7-8000 rare diseases, but because of their rarity, they […]
The worldwide demand for seafood is rising while the supply of fish is diminishing. BlueNalu is working to close that gap through cellular aquaculture – manufacturing fish meat in bioreactors. It begins with a fish […]
Jeane Wong calls herself a bus driver for bigger brains. She has built a community of scientists who are sharing their knowledge and experience with kids in San Diego Schools.The Leagues’s origin story could have […]
Stanley Maloy is a life scientist and the Associate Vice President for Research and Innovation at San Diego State University. He has a passion for entrepreneurship. We often think some people have a gift for […]
In this episode, Mary Canady, the founder of the San Diego Biotech Network and Chris Conner, the host of Life Science Marketing Radio, talk about their collaboration and vision for the podcast.
[…]
This content is sponsored by Drug Information Association, Inc.? We?ve been covering the many ways San Diego life science researchers and professionals can grow from attending DIA 2019, and of course we?re overjoyed that there […]
This content is sponsored by Drug Information Association, Inc.? If you?re following our Drug Information Association 2019 (DIA 2019) blog series, you know that we have outlined some great reasons for San Diego scientists and […]
We had a very successful set of 2 SDBN Lunch On Us events last week. We had set out to rethink vendor shows by leveraging the SDBN in several ways: Providing more marketing to sponsors […]
This content is sponsored by Drug Information Association, Inc.? You may have seen a recent blog post in which Scripps Research graduate Sudip Parikh, now Senior Vice President of the Drug Information Association (DIA), talks […]
Novartis has taken up its option to license antisense oligonucleotide TQJ230, triggering a $150 million payout that Akcea Therapeutics will share with Ionis Pharmaceuticals. The decision sets Novartis up to test the RNA-targeting drug in […]
Copyright © 2026 Biotech Networks, LLC
